Sanara MedTech Inc. (SMTI) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
20.27
↓-13% vs avg
5yr avg: 23.37
30Y Low23.4·High65.9
P/FCF
78.85
↓-15% vs avg
5yr avg: 93.17
30Y Low10.8·High93.2
P/B Ratio
↑
27.75
↑+115% vs avg
5yr avg: 12.93
30Y Low5.0·High122.1
ROE
↓
-167.5%
↑-214% vs avg
5yr avg: -53.4%
30Y Low-231%·High323%
Debt/EBITDA
4.84
+0% vs avg
5yr avg: 4.84
30Y Low4.8·High6.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SMTI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sanara MedTech Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 78.9x P/FCF, 15% below the 5-year average of 93.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $170M | $201M | $282M | $340M | $360M | $217M | $286M | $34M | $7M | $13M | $4M |
| Enterprise Value | $202M | $233M | $298M | $347M | $352M | $199M | $286M | $30M | $7M | $13M | $5M |
| P/E Ratio → | -4.38 | — | — | — | — | — | — | — | — | 65.08 | — |
| P/S Ratio | 1.65 | 1.95 | 3.25 | 5.24 | 7.85 | 8.99 | 18.36 | 2.92 | 1.12 | 1.99 | 0.80 |
| P/B Ratio | 27.75 | 33.96 | 7.24 | 7.63 | 8.62 | 7.20 | 49.00 | 5.37 | 5.86 | 122.09 | — |
| P/FCF | 78.85 | 93.17 | — | — | — | — | — | — | 24.25 | — | 10.80 |
| P/OCF | 25.11 | 29.67 | — | — | — | — | — | — | 23.51 | — | 10.72 |
P/E links to full P/E history page with 30-year chart
SMTI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Sanara MedTech Inc.'s enterprise value stands at 20.3x EBITDA, 13% below its 5-year average of 23.4x. The Healthcare sector median is 14.4x, placing the stock at a 41% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.26 | 3.44 | 5.34 | 7.67 | 8.23 | 18.36 | 2.53 | 1.25 | 2.10 | 0.94 |
| EV / EBITDA | 20.27 | 23.37 | — | — | — | — | — | — | — | 65.92 | — |
| EV / EBIT | 27.66 | — | — | — | — | — | — | — | — | 28.93 | — |
| EV / FCF | — | 107.80 | — | — | — | — | — | — | 27.11 | — | 12.73 |
SMTI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Sanara MedTech Inc. earns an operating margin of 7.1%. Operating margins have expanded from -6.5% to 7.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -167.5% indicates the company is currently destroying shareholder equity. ROIC of 11.8% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.7% | 92.7% | 90.6% | 87.9% | 86.1% | 90.4% | 89.6% | 89.7% | 91.3% | 87.2% | 82.9% |
| Operating Margin | 7.1% | 7.1% | -7.7% | -6.5% | -27.3% | -30.6% | -32.3% | -23.3% | -8.6% | 1.9% | -4.9% |
| Net Profit Margin | -36.4% | -36.4% | -11.2% | -6.6% | -17.3% | -32.8% | -27.9% | -23.9% | -10.3% | 5.3% | -7.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -167.5% | -167.5% | -23.1% | -10.0% | -22.1% | -44.0% | -71.2% | -75.0% | -98.9% | 323.1% | — |
| ROA | -58.9% | -58.9% | -11.9% | -6.4% | -16.3% | -34.3% | -41.6% | -39.7% | -22.8% | 15.1% | -23.3% |
| ROIC | 11.8% | 11.8% | -9.5% | -7.5% | -41.3% | -62.2% | -97.5% | -109.3% | -27.7% | 15.0% | -55.8% |
| ROCE | 15.6% | 15.6% | -10.1% | -7.8% | -31.8% | -40.2% | -68.2% | -49.3% | -36.6% | 27.4% | -76.7% |
SMTI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Sanara MedTech Inc. carries a Debt/EBITDA ratio of 4.8x, which is highly leveraged (47% above the sector average of 3.3x). Net debt stands at $32M ($48M total debt minus $17M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 8.13 | 8.13 | 0.83 | 0.26 | 0.02 | 0.01 | 0.08 | 0.33 | 1.35 | 11.70 | — |
| Debt / EBITDA | 4.84 | 4.84 | — | — | — | — | — | — | — | 5.97 | — |
| Net Debt / Equity | — | 5.33 | 0.42 | 0.15 | -0.20 | -0.60 | 0.00 | -0.71 | 0.69 | 7.19 | — |
| Net Debt / EBITDA | 3.17 | 3.17 | — | — | — | — | — | — | — | 3.66 | — |
| Debt / FCF | — | 14.63 | — | — | — | — | — | — | 2.86 | — | 1.93 |
| Interest Coverage | — | — | -2.15 | -8.86 | -43.96 | -10374.34 | -436.73 | -25.87 | -5.80 | 0.95 | -1.56 |
SMTI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.80x means Sanara MedTech Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.38x to 1.80x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.80 | 1.80 | 2.18 | 1.38 | 1.61 | 4.09 | 1.27 | 3.35 | 2.42 | 0.96 | 1.43 |
| Quick Ratio | 1.59 | 1.59 | 2.00 | 1.04 | 1.33 | 3.75 | 0.94 | 3.07 | 1.27 | 0.63 | 1.18 |
| Cash Ratio | 0.89 | 0.89 | 1.04 | 0.37 | 0.70 | 3.10 | 0.13 | 2.50 | 1.81 | 0.22 | 0.60 |
| Asset Turnover | — | 2.62 | 0.98 | 0.88 | 0.75 | 0.66 | 1.59 | 1.06 | 1.92 | 2.84 | 2.54 |
| Inventory Turnover | 1.90 | 1.90 | 2.96 | 1.66 | 1.79 | 1.13 | 1.41 | 1.62 | 1.09 | 1.13 | 2.71 |
| Days Sales Outstanding | — | 42.47 | 57.07 | 47.92 | 55.77 | 45.20 | 53.08 | 41.42 | 10.28 | 48.43 | 52.64 |
SMTI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sanara MedTech Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 3.4% | 0.3% | 1.1% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | 1.5% | — |
| FCF Yield | 1.3% | 1.1% | — | — | — | — | — | — | 4.1% | — | 9.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.4% | 0.3% | 1.1% |
| Shares Outstanding | — | $9M | $8M | $8M | $8M | $7M | $6M | $2M | $2M | $2M | $1M |
Peer Comparison
Compare SMTI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SMTIYou | $170M | -4.4 | 20.3 | 78.9 | 92.7% | 7.1% | -167.5% | 11.8% | 4.8 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 XTNT | $80M | -4.8 | — | — | 58.2% | -10.3% | -34.9% | -12.8% | — |
 MDXG | $548M | 11.5 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 KROS | $433M | 5.1 | 2.3 | 4.1 | 99.4% | 28.9% | 19.9% | 167.9% | 0.2 |
 BLCO | $6B | -15.6 | 17.5 | — | 54.8% | 3.7% | -5.5% | 1.2% | 8.8 |
 CWST | $5B | 712.1 | 15.7 | 63.2 | 17.1% | 4.9% | 0.5% | 2.6% | 3.0 |
 HROW | $1B | -278.9 | — | — | 75.1% | 11.2% | -8.5% | 9.5% | — |
 SRDX | $615M | -52.4 | 200.6 | — | 73.8% | -4.5% | -9.7% | -3.7% | 10.9 |
 WST | $23B | 47.3 | 30.8 | 49.5 | 35.9% | 20.1% | 16.9% | 17.5% | 0.6 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 25 years · Updated daily
See SMTI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SMTI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SMTI vs NVCR
Side-by-side business, growth, and profitability comparison vs NovoCure Limited.
Start ComparisonSMTI — Frequently Asked Questions
Quick answers to the most common questions about buying SMTI stock.
What is Sanara MedTech Inc.'s P/E ratio?
Sanara MedTech Inc.'s current P/E ratio is -4.4x. The historical average is 65.1x.
What is Sanara MedTech Inc.'s EV/EBITDA?
Sanara MedTech Inc.'s current EV/EBITDA is 20.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 44.6x.
What is Sanara MedTech Inc.'s ROE?
Sanara MedTech Inc.'s return on equity (ROE) is -167.5%. The historical average is -56.2%.
Is SMTI stock overvalued?
Based on historical data, Sanara MedTech Inc. is trading at a P/E of -4.4x. Compare with industry peers and growth rates for a complete picture.
What are Sanara MedTech Inc.'s profit margins?
Sanara MedTech Inc. has 92.7% gross margin and 7.1% operating margin.
How much debt does Sanara MedTech Inc. have?
Sanara MedTech Inc.'s Debt/EBITDA ratio is 4.8x, indicating high leverage. A ratio above 4x may signal elevated financial risk.